MoneyWorks4Me

NATCO Pharma informs about disclosure

09 Nov 2022 Evaluate

NATCO Pharma has informed that it enclosed the disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 regarding ‘NATCO Announces Launch of First Generic Version of Pomalyst® (Pomalidomide) Capsules in the Australian Market’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..